Literature DB >> 30811791

A comprehensive program for preterm infants with patent ductus arteriosus.

Leah Apalodimas1, Benjamin Rush Waller Iii1, Ranjit Philip1, Judy Crawford1, Jorden Cunningham1, Shyam Sathanandam1.   

Abstract

OBJECTIVES: Patent ductus arteriosus (PDA) is a common finding in preterm infants. A hemodynamically significant PDA may require intervention for closure. This article aims to describe a transcatheter PDA closure (TCPC) program for preterm infants and the components of a comprehensive outpatient follow-up strategy.
SETTING: A multidisciplinary team approach including neonatology, cardiology, anesthesiology, medical transport team, pulmonology, cardiac surgery, neurodevelopmental specialist, nutrition, speech therapy, social work, research collaborators, and other health care specialists is integral to the dedicated care and promotion of wellness of extremely low birth weight (ELBW) infants. PATIENTS: To date, we have performed TCPC on 134 ELBW infants weighing <2 kg at the time of the procedure, 54 of whom were <1 kg with the smallest weighing 640 g with a median gestation age of 25 weeks (range 23-27 weeks).
INTERVENTIONS: A comprehensive follow-up strategy with the creation of the Memphis PDA Clinic was implemented. OUTCOME MEASURES: Respiratory support, tolerance of enteral feeds, growth, and neurodevelopmental progress are indicators of favorable outcomes.
RESULTS: TCPC has benefited ELBW infants with faster weaning off the ventilator, increase in enteral feedings, and somatic growth with the overall shortening of the hospital length of stay. The Memphis PDA Clinic has ensured optimal postdischarge follow-up to improve long-term outcomes.
CONCLUSIONS: TCPC is a safe and effective alternative to manage ELBW infants with a hemodynamically significant PDA. Comprehensive follow-up after discharge provided in a multispecialty clinic developed specifically for this unique population has been successful in improving outcomes.
© 2019 Wiley Periodicals, Inc.

Entities:  

Keywords:  extremely low birth weight; neonatology; neurodevelopmental outcomes; patent ductus arteriosus; pediatrics; preterm infant; transcatheter PDA closure

Mesh:

Year:  2019        PMID: 30811791     DOI: 10.1111/chd.12705

Source DB:  PubMed          Journal:  Congenit Heart Dis        ISSN: 1747-079X            Impact factor:   2.007


  6 in total

Review 1.  Percutaneous Closure of Patent Ductus Arteriosus.

Authors:  Megan Barcroft; Christopher McKee; Darren P Berman; Rachel A Taylor; Brian K Rivera; Charles V Smith; Jonathan L Slaughter; Afif El-Khuffash; Carl H Backes
Journal:  Clin Perinatol       Date:  2022-01-21       Impact factor: 3.430

Review 2.  Pulmonary Hypertension with Prolonged Patency of the Ductus Arteriosus in Preterm Infants.

Authors:  Ranjit Philip; Vineet Lamba; Ajay Talati; Shyam Sathanandam
Journal:  Children (Basel)       Date:  2020-09-16

Review 3.  Management of Patent Ductus Arteriosus in Premature Infants in 2020.

Authors:  Sarah Parkerson; Ranjit Philip; Ajay Talati; Shyam Sathanandam
Journal:  Front Pediatr       Date:  2021-02-11       Impact factor: 3.418

4.  Trend and Outcomes for Surgical Versus Transcatheter Patent Ductus Arteriosus Closure in Neonates and Infants at US Children's Hospitals.

Authors:  Michael T Kuntz; Steven J Staffa; Dionne Graham; David Faraoni; Philip Levy; James DiNardo; Nicola Maschietto; Viviane G Nasr
Journal:  J Am Heart Assoc       Date:  2021-12-31       Impact factor: 6.106

Review 5.  Consensus Guidelines for the Prevention and Management of Periprocedural Complications of Transcatheter Patent Ductus Arteriosus Closure with the Amplatzer Piccolo Occluder in Extremely Low Birth Weight Infants.

Authors:  Shyam Sathanandam; Dan Gutfinger; Brian Morray; Darren Berman; Matthew Gillespie; Thomas Forbes; Jason N Johnson; Ruchira Garg; Sophie Malekzadeh-Milani; Alain Fraisse; Osman Baspinar; Evan M Zahn
Journal:  Pediatr Cardiol       Date:  2021-06-30       Impact factor: 1.655

6.  PDA: Does it matter?

Authors:  Jalal M Abu-Shaweesh; Eyad Almidani
Journal:  Int J Pediatr Adolesc Med       Date:  2019-12-03
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.